Autoimmune pancreatitis as a risk factor of pancreatic cancer

Česká verze

Authors: D. Solil ¹; P. Dítě ^1,2; B. Kianička ³; M. Bojková ⁴; M. Uvírová ⁵; M. Přecechtělová ¹; J. Dolina ¹
Authors place of work: Interní gastroenterologická klinika LF MU a FN Brno ¹; LF OU Ostrava ²; II. interní klinika LF MU a FN U sv. Anny v Brně ³; Gastroenterologické oddělení, Interní klinika kardiologická LF OU a FN Ostrava ⁴; EUC – CGB Laboratoř Ostrava ⁵
Published in the journal: Klin Onkol 2024; 39(6): 420-426
Category: Přehledy
doi: https://doi.org/10.48095/ccko2024420

Summary

Background: Autoimmune pancreatitis (AIP) is a form of chronic pancreatitis that presents clinically with obstructive icterus, histologically with infiltration of pancreatic parenchyma by inflammatory cells leading to chronic inflammation with fibrosis, and therapeutically with good response to corticosteroid therapy. Clinically, it may resemble malignant disease, making diagnosis difficult and requiring a multidisciplinary team (gastroenterologist, endoscopist, radiologist, surgeon, pathologist). Two types of AIP are distinguished. Type 1 is associated with elevated serum immunoglobulin IgG4 and systemic manifestations (IgG4 related diseases). Type 2, without IgG4 elevation, is typically associated with the occurrence of idiopathic inflammatory bowel disease, especially ulcerative colitis. The first line treatment of symptomatic AIP is corticotherapy with an initial dose of 0.6–1 mg/kg/day for the first 2–4 weeks, followed by a gradual de-escalation to prevent frequent relapses. Chronic inflammation, or chronic pancreatitis, is a well-known risk factor for the development of malignancy. The association between carcinogenesis and AIP is widely discussed, but due to the rarity of the disease and a small number of studies, risk estimates vary. Pancreatic carcinoma development is most common in patients with type 1 autoimmune pancreatitis. However, it has been observed that the incidence of extra-pancreatic cancer (stomach, lung, and prostate cancer) is often equal or even higher. It is also considered that AIP may develop from coexisting malignancies as a paraneoplastic syndrome. Screening of patients with AIP for potential carcinogenesis should not be overlooked. Purpose: The aim of this review article is to point out a rare (autoimmune) form of chronic pancreatitis with the necessity of follow up with regard to the potential risk of malignancy.

Keywords:

Pancreatic cancer – chronic pancreatitis – autoimmune pancreatitis – IgG4 related diseases

Zdroje

1. Yoshida T, Toki F, Takeuchi T et al. Chronic pancreatitis caused by autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis. Dig Dis Sci 1995; 40 (7): 1561–1568. doi: 10.1007/BF02285209.

2. Stone JH, Klosroshah A, Desphande V et al. Recommendation for the nomenclature f IgG4 related disease and its individual organ systém manifestations. Arthritis Rheum 2012; 64 (10): 3061–3067. doi: 10.1002/art.34593.

3. Shimosegawa T, Chari ST, Frulloni L et al. International consensus diagnostic criteria for autoimmune pancreatitis, guidelines of the International Association of Pancreatology. Pancreas 2011; 40 (3): 352–358. doi: 10.1097/MPA.0b013e3182142fd2.

4. Nikolic S, Lanzillotta M, Panic N et al. Unraveling the relationship between autoimmune pancreatitis type 2 and inflammatory bowel disease: results from two centers and systematic review of the literature. United Eur Gastroenterol J 2022; 10 (5): 496–506. doi: 10.1002/ueg2.12237.

5. Dítě P, Novotný I, Kianička B et al. Autoimmune pancreatitis – diagnostic consensus. Vnitr Lek 2015; 61 (2): 114–118.

6. Masamune A, Kikuta K, Hamada S et al. Nationwide epidemiological survey of autoimmune pancreatitis in Japan in 2016. J Gastroenterol 2020; 55 (4): 462–470. doi: 10.1007/s00535-019-016587.

7. Barresi L, Tacelli M, Crinò SF et al. Multicentric Italian survey on daily practice for autoimmune pancreatitis: clinical data, diagnosis, treatment, and evolution toward pancreatic insufficiency. United Eur Gastroenterol J 2020; 8 (6): 705–715. doi: 10.1177/2050640620924302.

8. Psarras A, Emery P, Vital EM. Type I interferon-mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy. Rheumatology 2017; 56 (10): 1662–1675. doi: 10.1093/rheumatology/kew431.

9. Watanabe T, Minaga K, Kamata K et al. Mechanistic insights into autoimmune pancreatitis. Trends Immunol 2018; 39 (11): 874–889. doi: 10.1016/j.it.2018.09.005.

10. Zhiquan Z, Rigas B. NF-kapaB, inflammation and pancreatic cancerogenesis: NF-kapaB as a chemoprevention target (review). Int J Oncol 2006; 29 (1): 185–192.

11. Fujioka S, Sclabas GM, Schmidt C et al. Inhibition of constitutive NF-kapaB activity by I kappa B alpha M suppresses tumorigenesis. Oncogene 2003; 22 (9): 1365–1370. doi: 10.1038/sj.onc.1206323.

12. Garcea G, Neal CP, Pattenden CJ et al. Molecular prognostic markers in pancreatic cancer: a systematic review. Eur J Cancer 2005; 41 (15): 2213–2236. doi: 10.1016/j.ejca.2005.04.044.

13. Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004; 25 (6): 280–288. doi: 10.1016/j.it. 2004.03.008.

14. Sclaba GM, Uwagawa T, Shmidt C et al. Nuclear factor kappa B activation is a potential target for preventing pancreatic carcinoma by aspirin. Cancer 2005; 103 (12): 2485–2490. doi: 10.1002/cncr.21075.

15. Chandler NM, Canete JJ, Callery MP. Increased expression of NF-kappa B subunits in human pancreatic cancer cells. J Surg Res 2004; 118 (1): 9–14. 10.1016/S0022-4804 (03) 00354-8.

16. Sclaba GM, Fujoka S, Schmidt C et al. Restoring apoptosis in pancreatic cancer cells by targeting the nuclear factor-kappaB signaling pathway with the anti-epidermal growth factor antibody IMC-C 225. J Gastrointest Surg 2003; 7 (1): 37–43. doi: 10.1016/s1091-255x (02) 00088-4.

17. Liptay S, Weber CK, Ludwig L et al. Mitogenic and antiapoptotic role of constitutive NF-kappaB/Rel activity in pancreatic cancer. Int J Cancer 2003; 105 (6): 735–746. doi: 10.1002/ijc.11081.

18. Hart PA, Zen Y, Chari ST. Recent advances in autoimmune pancreatitis. Gastroenterology 2015; 149 (1): 39–51. doi: 10.1053/j.gastro.2015.03.010.

19. Chappuis PO, Ghadirian P, Foulkes WD. The role of genetic factors in the etiology of pancreatic adenocarcinoma: an update. Cancer Invest 2001; 19 (1): 65–75. doi: 10.1081/cnv-100000076.

20. Kawa S, Ota M, Yoshizawa K et al. HLA DRB10405-DQB10401 haplotype is associated with autoimmune pancreatits in Japanese population. Gastroenterology 2012; 122 (5): 1264–1269. doi: 10.1053/gast.2002.33022.

21. Löhr JM, Beuers U, Vujasinovic M et al. European Guideline on IgG4-related digestive disease – UEG and SGF evidence-based recommendations. United Eur Gastroenterol J 2020; 8 (6): 637–666. doi: 10.1177/2050640 620934911.

22. Okazaki K, Chari ST, Frulloni L et al. International consensus for the treatment of autoimmune pancreatitis. Pancreatology 2017; 17 (1): 1–6. doi: 10.1016/j.pan. 2016.12.003.

23. Overbeek KA, Poulsen JL, Lanzillotta M et al. Type 1 autoimmune pancreatitis in Europe: clinical profile and response to treatment. Clin Gastroenterol Hepatol 2024; 22 (5): 994–1004.e10. doi: 10.1016/j.cgh.2023.12.010.

24. Stein J, Jung M, Sziegoleit A et al. Immunoreactive elastase I: clinical valuation of a new noninvasive test of pancreatic function. Clin Chem 1996; 42 (2): 222–226.

25. Toth AZ, Szabo A, Hegyi P et al. Detection of human elastase isoforms by the ScheBo Pancreatic Elastase 1 Test. Am J Physiol Gastrointest Liver Physiol 2017; 312 (6): G606–G614. doi: 10.1152/ajpgi.00060.2017.

26. Sikkens EC, Cahen DL, Koch AD et al. The prevalence of fat-soluble vitamin deficiencies and a decreased bone mass in patients with chronic pancreatitis. Pancreatology 2013; 13 (3): 238–242. doi: 10.1016/j.pan.2013.02.008.

27. Dujsikova H, Dite P, Tomand J et al. Occurence of metabolic osteopathy in patients with chronic pancreatitis. Pancreatology 2008; 8 (6): 583–586. doi: 10.1159/000159845.

28. Duggan SN, Smyth ND, Murphy A et al. High prevalence of osteoporosis in patients with chronic pancreatitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2014; 12 (2): 219–228. doi: 10.1016/ j.cgh.2013.06.016.

29. Samarasekova E, Mahammed S, Carlisie S et al. Pancreatitis: summary of NICE guidance. BMJ 2018; 362: k3443. doi: 10.1136/bmj.k3443.

30. Dušek L, Mužík J, Kubásek M et al. Epidemiologie zhoubných nádorů v České republice. [online]. Dostupné z: http: //www.svod.cz.

31. Malka D, Hammel P, Maire F et al. Risk of pancreatic adenocarcinoma in chronic pancreatitis. Gut 2002; 51 (6): 549–552. doi: 10.1136/gut.51.6.849.

32. Kamisawa T, Tsuruta K, Okamoto A et al. Frequent and significant K-ras mutation in the pancreas, the bile duct, and the gallbladder in autoimmune pancreatitis. Pancreas 2009; 38 (8): 890–895. doi: 10.1097/MPA.0b0 13e3181b65a1c.

33. Bansal P, Sonnenberg A. Pancreatitis is a risk factor for pancreatic cancer. Gastroenterology 1995; 109 (1): 247–251. doi: 10.1016/0016-5085 (95) 90291-0.

34. Talamini G, Falconi M, Bassi C et al. Incidence of cancer in the course of chronic pancreatitis. Am J Gastroenterol 1999; 94 (5): 1253–1260. doi: 10.1111/j.1572-0241.1999.01075.x.

35. Howlader N, Noone AM, Krapcho M et al. SEER Cancer Statistics Review (CSR) 1975–2018. [online]. Dostupné z: https: //seer.cancer.gov/csr/1975_2018/.

36. Buijs J, Cahen DL, van Heerde MJ et al. The long-term impact of autoimmune pancreatitis on pancreatic function, quality of life, and life expectancy. Pancreas 2015; 44 (7): 1065–1071. doi: 10.1097/MPA.0000000000000451.

37. Shiokawa M, Kodama Y, Yoshimura K et al. Risk of cancer in patients with autoimmune pancreatitis. Am J Gastroenterol 2013; 108 (4): 610–617. doi: 10.1038/ajg.2012.465.

38. Kirkegård J, Mortensen FV, Cronin-Fenton D. Chronic pancreatitis and pancreatic cancer risk: a systematic review and meta-analysis. Am J Gastroenterol 2017; 112 (9): 1366–1372. doi: 10.1038/ajg.2017.218.

39. Macinga P, Bajer L, Del Chiaro M et al. Pancreatic cancer in patients with autoimmune pancreatitis: a scoping review. Pancreatology 2021; 21 (5): 928–937. doi: 10.1016/j.pan.2021.03.007.

40. Bojková M, Dítě P, Dvořáčková J et al. Immunoglobulin G4, autoimmune pancreatitis and pancreatic cancer. Dig Dis 2015; 33 (1): 86–90. doi: 10.1159/000368337.

41. Aslanian HR, Lee JH, Canto MI. AGA clinical practice update on pancreas cancer screening in high-risk individuals: expert review. Gastroenterology 2020; 159 (1): 358–362. doi: 10.1053/j. gastro.2020.03.088.

42. Goggins M, Overbeek KA, Brand R et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut 2020; 69 (1): 7–17. doi: 10.1136/gutjnl-2019- 319352.

43. Loveček M, Skalický P, Tesaříková J et al. Pancreatic cancer in chronic pancreatitis – the diagnostic and therapeutic dilemma; an overview of cases. Rozhl Chir 2022; 101 (11): 549–550. doi: 10.33699/PIS.2022.101.11.549-556.